Gina Wilvang
Primary Podiatric Medicine · Cerritos, CANPI 1407986995
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 31 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Organogenesis Inc. at 40.8% of the total. Reporting peaked in 2021 at $275 and has fallen 63.5% since, to $100 in 2025. That places this record below the midpoint for primary podiatric medicine clinicians in CA, where the typical reported total is $887.
Across 31 payments — averaging $23.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Organogenesis Inc.$302
- Averitas Pharma Inc.$89
- Smith+Nephew$85
- Inari Medical, Inc.$69
- Johnson & Johnson$67
- Merck$26
- plus $102 from 5 others
What the payments were for
- Food & beverage$742100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Organogenesis Inc. | 10 | $302 |
| Averitas Pharma Inc. | 3 | $89 |
| Smith+Nephew | 6 | $85 |
| Inari Medical, Inc. | 1 | $69 |
| Johnson & Johnson | 3 | $67 |
| Merck | 2 | $26 |
| Globus Medical | 1 | $25 |
| Bard Peripheral Vascular, Inc. | 2 | $22 |
| Biotissue Holdings Inc. | 1 | $19 |
| Stryker | 1 | $19 |
| Zimmer Biomet | 1 | $17 |
How this compares
$742 in reported general payments places this provider in the 45th percentile of 59 primary podiatric medicine providers in California.
See all primary podiatric medicine providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Diclofenac Sodium | 69 | $1,050 |
| Ciclopirox | 38 | $831 |
| Clotrimazole | 22 | $264 |
| Terbinafine Hcl | 14 | $239 |
Paid to pharmacies, not to this prescriber.
Other primary podiatric medicine in Cerritos
- James WangLos Angeles$250K
- Adam ShapiroUpland$21K
- Ali GhorbanifarajzadehBakersfield$17K
- Abid ChaudhryArleta$11K
- Matthew GarrisonSacramento$7K
- Linh HuynhTurlock$7K
- Yvette CanabaSantee$5K
- David KhakshoorLos Angeles$4K
- Katrina SergeevaVista$4K
- Christyn MarshallDanville$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.